Thirona Bio is developing a proprietary drug platform to treat both skin and lung fibrosis, as well as certain cancers. This targeted drug approach combines the unique properties of FBM5712, a small molecule kinase inhibitor of TGF-β, which is designed to be rapidly metabolized to reduce systemic exposure, with novel technology to maximize the local concentration of the drug in fibrotic tissue. The resulting therapies are organ-selective and locally acting inhibitors of TGF-β, the primary mediator of fibrosis. High local drug concentration & inhibition of all TGF-β isoforms maximize efficacy while organ targeting & rapid drug metabolism overcome the key historical safety challenges associated with TGF-β drug development. Thirona’s lead product, TBIO-101, achieves more than a 50,000-fold greater concentration of the drug in the dermis versus the plasma, minimizing systemic exposure and thereby the potential for systemic toxicity.